Panel 6 assesses PD1, PD-L1, and TIM-3 specifically as expressed on immune cells (CD4+PD-1+, CD4+TIM-3+, CD8+PD-1+ and CD8+TIM-3+) and tumour cells (SYN+PD-1+, SYN+TIM-3+ and SYN+PD-L1+). Here, HAVCR2 is linked to neoplasm.